These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Challenges in Ras therapeutics in pancreatic cancer. Choi M; Bien H; Mofunanya A; Powers S Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065 [TBL] [Abstract][Full Text] [Related]
8. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells. Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961 [TBL] [Abstract][Full Text] [Related]
9. Recapitulation of ras oncogene mutations in breast cancer. Stamatakos M; Stefanaki C; Kontzoglou K; Masouridi S; Sakorafas G; Safioleas M Onkologie; 2010; 33(10):540-4. PubMed ID: 20926903 [TBL] [Abstract][Full Text] [Related]
10. Targeting the RAS-dependent chemoresistance: The Warburg connection. Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815 [TBL] [Abstract][Full Text] [Related]
11. Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Weijzen S; Rizzo P; Braid M; Vaishnav R; Jonkheer SM; Zlobin A; Osborne BA; Gottipati S; Aster JC; Hahn WC; Rudolf M; Siziopikou K; Kast WM; Miele L Nat Med; 2002 Sep; 8(9):979-86. PubMed ID: 12185362 [TBL] [Abstract][Full Text] [Related]
12. RAS mutations in human cancers: Roles in precision medicine. Murugan AK; Grieco M; Tsuchida N Semin Cancer Biol; 2019 Dec; 59():23-35. PubMed ID: 31255772 [TBL] [Abstract][Full Text] [Related]
13. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis. Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801 [TBL] [Abstract][Full Text] [Related]
14. Report of a meeting: molecular basis of cancer therapy. Gottesman MM J Natl Cancer Inst; 1994 Sep; 86(17):1277-85. PubMed ID: 7914937 [TBL] [Abstract][Full Text] [Related]
16. RAS oncogene-mediated deregulation of the transcriptome: from molecular signature to function. Schäfer R; Sers C Adv Enzyme Regul; 2011; 51(1):126-36. PubMed ID: 21094659 [TBL] [Abstract][Full Text] [Related]
17. RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action. Masliah-Planchon J; Garinet S; Pasmant E Oncotarget; 2016 Jun; 7(25):38892-38907. PubMed ID: 26646588 [TBL] [Abstract][Full Text] [Related]
18. Aberrant function of the Ras signal transduction pathway in human breast cancer. Clark GJ; Der CJ Breast Cancer Res Treat; 1995 Jul; 35(1):133-44. PubMed ID: 7612899 [TBL] [Abstract][Full Text] [Related]
19. Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling. Dhawan NS; Scopton AP; Dar AC Nature; 2016 Sep; 537(7618):112-116. PubMed ID: 27556948 [TBL] [Abstract][Full Text] [Related]
20. K-ras as a target for cancer therapy. Friday BB; Adjei AA Biochim Biophys Acta; 2005 Nov; 1756(2):127-44. PubMed ID: 16139957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]